Safety and Efficacy Study of Bimosiamose Cream to Treat Psoriasis

Revotar Biopharmaceuticals AG107 enrolled

Overview

The purpose of this study is to determine whether Bimosiamose Cream is safe and effective in the treatment of plaque type psoriasis.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

107

Conditions

Psoriasis

Interventions

Bimosiamose CreamDRUG

Placebo CreamDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Clinical diagnosis of plaque type psoriasis PASI score of 5-15 * At least 18 years of age * Written informed consent Exclusion Criteria: * Active skin infection * More than 20% Body Surface Area (BSA) affected by psoriasis * Use of certain anti-psoriasis medication or treatments

Locations (1)

Charité Campus Mitte, Klinik für Dermatologie, Venerologie und Allergologie

Berlin, Germany

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.